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Abstract
Background: Patients with pulmonary arterial hypertension (PAH) and other forms of precapillary pulmonary
hypertension (PH) have impaired quality of life (QoL). The Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR) is a PH-specific patient-reported outcome measure that assesses symptoms, activity limitations and
QoL. It was originally developed in UK-English. The main objective of this study was to create an adaptation of the
CAMPHOR suitable for a Portuguese-speaking population.
Methods: A multi-step approach was followed: bilingual and lay panel translation; cognitive debriefing interviews;
and psychometric testing in repeated postal surveys (2 weeks apart) including assessment of internal consistency,
reproducibility and validity. The Nottingham Health Profile (NHP) questionnaire was used as a comparator
instrument to test convergent validity.
Results: The CAMPHOR was translated without difficulty by the two panels. Cognitive debriefing interviews showed
the questionnaire was easily understood and considered relevant to patients’ experience with their illness. Psychometric
evaluation was performed with 50 PAH patients (47 ± 14 years, 37 women). Cronbach’s alpha coefficients showed good
internal consistency for the three CAMPHOR scales [Symptoms = 0.95; Activities = 0.93 and QoL = 0.94]. Test-retest
coefficients showed that all scales had excellent reliability (Symptoms = 0.94; Activities = 0.89 and QoL = 0.93), indicating
low levels of random measurement error. The CAMPHOR correlated as expected with the NHP. The magnitude of
correlations followed a similar pattern to those in the original development study. The CAMPHOR also exhibited
evidence of known group validity in its ability to distinguish between self-reported severity and general health groups.
Conclusions: A valid and reliable version of the CAMPHOR questionnaire for the European Portuguese-speaking
population was developed and is recommended for use.
Keywords: Pulmonary hypertension, Precapillary pulmonary hypertension, Pulmonary arterial hypertension, Quality of
life, CAMPHOR, Portuguese adaptation, Nottingham Health Profile
Background
Precapillary pulmonary hypertension (PH) is characterized
by an obstructive vasculopathy of the pulmonary circula-
tion leading to increased pulmonary arterial pressure, pul-
monary vascular resistance and, eventually, right-sided
heart failure and death [1–4]. Multiple conditions and
comorbidities are associated with PH [5]. Patients present
unspecific symptoms, such as exertion dyspnoea, fatigue,
chest pain, palpitations, oedema or syncope, resulting in
frequently delayed diagnosis [4].
PH prognosis improved in recent years due to better un-
derstanding of PH pathobiology, availability of new drugs
(endothelin receptor antagonists, phosphodiesterase-5 in-
hibitors, soluble guanylate cyclase stimulators and prosta-
cyclin analogues) and renewed therapeutic strategies [6–9].
Still, a cure for pulmonary arterial hypertension (PAH) and
other precapillary forms of PH is far from being available.
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The impact of the disease and some types of treatment,
like parenteral drugs or oxygen administration, can lead to
impaired QoL, social isolation, as well as anxiety and de-
pression [10]. Assessments of health-related quality of life
(HRQoL) are currently recommended during global evalu-
ation of PH patients, both in the context of clinical trials
and routine clinical practice. Although some generic ques-
tionnaires such as the Short Form 36 Health Survey (SF-
36) have shown prognostic value in PAH [11, 12], generally
the use of generic questionnaires or those specific to other
conditions has important limitations if they are not even-
tually validated in an appropriate PH sample [13]. Several
attempts to evaluate other generic questionnaires, such as
Nottingham Health Profile (NHP), and EuroQol Group 5-
Dimension Self-Report Questionnaire (EQ-5D) or other
disease-specific questionnaires, such as the Minnesota Liv-
ing with Heart Failure Questionnaire (MLHFQ) or the
Chronic Heart Failure questionnaire (CHQ), have failed to
prove their specificity for the disease both in real life
settings and clinical trials [14–21]. This lead to the devel-
opment of disease-specific questionnaires such as the
Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR) [12, 13], and more recently, the emPHasis-
10 [22] and the Pulmonary Arterial Hypertension-
Symptoms and Impact (PAH-SYMPACT) [23], which are
under evaluation. Disease-specific assessment instruments
provide outcome measures that are more relevant to ac-
tual patient experience. Evidence also demonstrates that
these outcomes are more sensitive to change than generic
ones [24–29].
The CAMPHOR was originally developed and validated
in the United Kingdom, [30] and subsequently adapted for
use in the US, Canada, Australia/New Zealand, Sweden
and Austria/Germany/Switzerland [13, 31–34]. It consists
of three different scales: a 25-item Symptom scale, to as-
sess energy, breathlessness and mood (low score indicates
minimal symptoms); a 15-item Activity limitations scale
with a 3-point rating system (score ranges from 0 to 30,
lower score indicates minimal activity limitation); and a
25-item QoL scale (lower score indicates better QoL) [30].
This paper describes the Portuguese translation and val-
idation of the CAMPHOR. The development of this lan-
guage version will allow the use of CAMPHOR in routine
clinical practice and in clinical trials in the European
Portuguese-speaking population with PAH and other pre-
capillary forms of PH.
Methods
CAMPHOR translation and validation was based in
three main stages: (1) bilingual and lay panel translation;
(2) cognitive debriefing interviews; and (3) psychometric
testing in repeated postal surveys, 2 weeks apart. Psy-
chometric analyses included test-retest reliability, in-
ternal consistency, convergent validity, and known group
validity. The study was approved by the Independent
Ethics Committee of Centro Hospitalar do Porto and
written informed consent was obtained from all partici-
pants before enrolment in the study.
Step 1: Translation
The bilingual panel involved a group of six
participants who had Portuguese as their primary
language and were fluent in Portuguese and English.
Participants were excluded if they had medical
training, were a professional translator or if they were
familiar with PH. The Principal Investigator lead the
panel discussion and a representative of the original
measure development team attended the meeting,
advising in situations of difficult decision-making by
explaining the original concept of the items. Each
scale item was discussed until agreement was
reached.
The main goal of this panel was to provide the initial
translation of the questionnaire. When translating the
content, emphasis was placed on achieving conceptual
equivalence rather than providing a literal translation.
In situations where agreement could not be reached,
the panel provided alternative translations for later
consideration by the lay panel.
A separate lay translation panel consisted of a group
of five monolingual Portuguese-speaking participants
with an average education level. The Portuguese
translation of the questionnaire developed by the
bilingual panel was presented and discussed. Participants
were asked to comment on the language in terms of
comprehension and acceptability. The main goal of this
panel was to ensure that the language used in the
questionnaire was adequate for respondents with
average educational level.
Step 2: Cognitive Debriefing Interviews
Face-to-face cognitive debriefing interviews were
conducted with 10 patients in the PH outpatient
clinic at Centro Hospitalar do Porto—Hospital Santo
António (Table 1). The purpose of the interviews was
to assess the relevance, acceptability, comprehensiveness
and understandability of the questionnaire items.
During the interviews, participants were asked to
complete the questionnaire, comment on any aspect
they thought had been omitted and answer some
specific questions about the questionnaire.
Step 3: Validation
To validate the Portuguese version of the CAMPHOR,
50 patients with precapillary PH were recruited in
the outpatient clinic at Centro Hospitalar do
Porto—Hospital Santo António, between 14SEP2012
and 16SEP2013. Their mean disease duration was
57.06 (SD = 58.81) months. During a programmed
visit, participants were informed about the study
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methodology, signed an informed consent form and
received packs containing written instructions, two
samples of the CAMPHOR and NHP questionnaires
(to be filled in at home, 2 weeks apart) and a pre-paid
postal return envelope. All participants received unique
identification numbers. Only returned completed
surveys were considered for analysis.
Demographic (birth date, gender, marital and
working status) and clinical data (PH aetiology,
WHO/NYHA functional class, 6MWD, NT-proBNP,
treatment) were gathered from the PH clinic dedicated
informatics system (PAHTool®, Inovultus Lda,
Portugal) and exported to Microsoft Excel.
Statistical analysis
The distributional properties of the measures were ex-
plored through descriptive statistics [mean, standard de-
viation, median and interquartile range (IQR) and floor
and ceiling effects (% of patients scoring the minimum
and maximum scores)]. Scores were compared by age
and gender.
Internal consistency was assessed using Cronbach’s
alpha coefficients. Alpha measures the extent to which
the items in a scale are inter-related. A low alpha (below
0.7) indicates that the items do not work together to
form a scale [25]. In addition, item total correlations
(ITCs) should be between 0.2 and 0.8.
The test-retest reliability of a measure is an estimate
of its reproducibility over time when no change in the
condition has taken place. It is calculated by correlating
scores obtained on two different occasions. Spearman’s
rank correlation coefficient was used for the analyses.
For low random measurement error, a correlation coeffi-
cient of ≥0.85 is necessary (26).
Convergent validity is used to determine the level of
association between scores on one scale and those on a
comparator scale that measures the same or related con-
structs. For the present investigation, the NHP was used
as a comparator instrument. Portuguese CAMPHOR
scores were correlated with NHP scores by Spearman
rank correlation coefficients.
Known group validity can be assessed by testing the
ability of a measure to distinguish between groups of
people that differ according to some known factor. The
factors used for the present investigation were self-
reported general health (poor, fair, good, very good) and
severity of symptoms (mild, moderate and severe).
Non-parametric tests for independent samples (Mann-
Whitney U Test for two groups or Kruskal-Wallis One-
Way Analysis of Variance for three or more groups)
were employed to test for differences in CAMPHOR
scores between groups.
Statistical analyses were performed using IBM SPSS
version 21.0.
Results
Translation
Equal numbers of men and women (3 males and 3 fe-
males) were included in the bilingual panel. The mean
age of the participants was 37 years (range 21–52 years).
Most of the translation process occurred with little dis-
cussion and disagreement between panel participants.
The main challenge during the translation was the selec-
tion of words that would allow the items to be expressed
colloquially.
The lay panel involved one male and four female partici-
pants with a mean age of 37 years (range 16–66 years).
The panel reported that the language of the questionnaire
Table 1 Demographic and baseline characteristics of the study
samples
Parameter Cognitive debriefing
interview panel
(n = 10)
Psychometric
testing panel
(n = 50)
Gender, n (%)
Male 3 (30.0) 13 (26.0)
Female 7 (70.0) 37 (74.0)
Age, years
Mean 47.8 46.8
Range 23–70 20–75
Marital Status, n (%)
Single 3 (30.0) 12 (24.0)
Married/living as married 5 (50.0) 35 (70.0)
Divorced/Separated 2 (20.0) 3 (6.0)
Employment Status, n (%)
Student 0 (0.0) 2 (4.0)
Full-time 2 (20.0) 16 (32.0)
Part-time 1 (10.0) 0 (0.0)
Unemployed 1 (10.0) 0 (0.0)
Retired 5 (50.0) 23 (46.0)
Long-term sick leave 1 (10.0) 0 (0.0)
Homemaker 0 (0.0) 9 (18.0)
PH aetiology, n (%)
Idiopathic/Heritable PAH 3 (30.0) 12 (24.0)
Connective Tissue Disorders 1 (10.0) 7 (14.0)
Human Immunodeficiency Virus 0 (0.0) 1 (2.0)
Porto-Pulmonary Hypertension 0 (0.0) 3 (6.0)
Congenital Heart Disease 3 (30.0)) 11 (22.0)
Interstitial Lung Disease 0 (0.0) 1 (2.0)
Chronic Thromboembolic
Pulmonary Hypertension
3 (30.0) 12 (24.0)
PH with unclear multifactorial
mechanisms
0 (0.0) 2 (4.0)
Mixed 0 (0.0) 1 (2.0)
Abbreviations: PH pulmonary hypertension
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was generally good, objective, direct, and clear. However,
panel members suggested some alternative wording to im-
prove understanding. For example, item 1 of the Symp-
toms scale was changed because the Lay Panel thought
that “without strengths” rather than “low strengths” would
be easier to understand.
Cognitive debriefing interviews
All CAMPHOR questionnaires were completed within a
mean of 17 min (standard deviation 10.5 min). In general,
patients understood the questionnaire and assessed it as
being simple and easy to complete. Three elderly, rural,
low literacy patients needed supplementary information to
fully understand the instructions. All patients found that
the questionnaire reflected their health condition and daily
activities. The questionnaire’s content was considered ap-
propriate, relevant and comprehensive. No questionnaire
items were identified as inappropriate or unacceptable.
Validation
Fifty patients were recruited (Time 1) and 47 (94 %)
completed and returned the questionnaires. Three sub-
jects withdrew from the study, one was lost to follow up
and two others were submitted to surgery between the
surveys. The mean time between repeated post surveys
was 14.2 days (median 14.0; n = 47). Main PH aetiologies
are shown in Table 1.
Sample demographics
Table 1 shows participants’ characteristics and Table 2
presents disease information at Time 1.
Questionnaire descriptive scores
Descriptive statistics at Time 1 and Time 2 are shown in
Table 3.
Floor (>10 % of patients scoring minimum) effects were
identified in the CAMPHOR QoL scale Time 1 and the
CAMPHOR QoL and Symptoms scales at Time 2. How-
ever, this is likely to reflect the mild nature of a subgroup
of the sample. A possible ceiling effect might have oc-
curred, since 16.3 % of the patients reached the maximum
score in the QoL scale at Time 1. These effects were ob-
served in the NHP scales.
Internal consistency and reproducibility
Cronbach’s alpha coefficients results are summarized in
Table 4. The scales of Portuguese CAMPHOR showed
excellent internal consistency with scales ranging be-
tween (0.93 and 0.95). Inter-item total correlations for
each item are shown in Additional file 1: Tables S1, S2,
S3. Reproducibility was above the required 0.85 level for
all three CAMPHOR scales: Symptoms = 0.94, Activity
limitations = 0.89 and QoL = 0.93.
Convergent reliability
Table 5 shows the correlation between CAMPHOR and
NHP (six sections and NHP-D) scales at Time 1. High
correlations were observed between CAMPHOR symp-
toms and Emotional reactions, Physical mobility and En-
ergy showing the importance of these factors on PH
symptomatology. As expected, CAMPHOR Activities
correlated more strongly with Physical mobility. The
QoL scale correlated more strongly with Energy, Emo-
tional reactions, Physical mobility and Overall distress,
indicating that multiple factors influence QoL in PH.
Association of CAMPHOR scores with demographic
factors
No significant differences in CAMPHOR scores were
found between participants grouped by age (above ver-
sus below median age) or gender.
Known group validity
Table 6 shows the results of the known groups analyses.
Significant differences in ASQoL scores were observed
between patients grouped by overall general health and
perceived severity of disease.
Discussion
Current guidelines recommend initial and follow-up dis-
ease severity and QoL assessments to support decisions
regarding PH treatment [35]. Previous validation of the
CAMPHOR questionnaire in other geographical and
cultural contexts demonstrated its superior specificity
for PH versus general questionnaires, such as NHP, SF-
36 or LHFQ. Furthermore, the development of the
Table 2 Disease information of the Psychometric testing panel
Parameter Psychometric testing panel (n = 50)
Self-reported general health, n (%)
Poor 4 (8.3)
Fair 2 (4.2)
Good 11 (22.9)
Very Good 31 (64.6)
Self-reported severity of disease, n (%)
Mild 6 (12.2)
Moderate 24 (49.0)
Severe 19 (38.8)
Flare up, n (%)
No 41 (83.7)
Yes 8 (16.3)
Requirement of oxygen or aids, n (%)
No 28 (57.1)
Yes 21 (42.9)
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CAMPHOR utility index added the possibility of cost-
utility analyses, which is particularly relevant for PH dis-
ease management [36].
Our study demonstrates that our European Portuguese
version of CAMPHOR is a valid, internally consistent and
reliable patient-reported outcome measure for the European
Portuguese-speaking population with precapillary PH. This
study was conducted exclusively in Portugal, therefore the
Table 3 Questionnaire descriptive statistics for Time 1 and Time 2
Parameter n Median (IQR) Mean (SD) Min–Max % Max scoring % Min scoring
Time 1
CAMPHOR
Symptoms 45 6.0 (3.0–15.5) 9.4 (7.9) 0.0–25.0 8.9 2.2
Activities 45 10.0 (6.0–16.0) 11.2 (6.4) 2.0–27.0 4.4 2.2
QoL 43 6.0 (1.0–14.0) 8.1 (7.3) 0.0–25.0 16.3 2.3
NHP
Energy Scale 47 0.0 (0.0–33.3) 27.0 (37.2) 0.0–100.0 57.4 14.9
Pain Scale 48 0.0 (0.0–37.5) 20.3 (31.1) 0.0–100.0 58.3 2.1
Emotional Reactions 48 22.2 (11.1–44.4) 27.8 (24.8) 0.0–88.9 22.9 2.1
Sleep Scale 47 20.0 (0.0–60.0) 30.2 (34.6) 0.0–100.0 44.7 8.5
Social Isolation 49 0.0 (0.0–20.0) 13.9 (24.2) 0.0–80.0 71.4 2.0
Physical Mobility 47 12.5 (0.0–50.0) 26.3 (26.2) 0.0–87.5 29.8 2.1
NHP-D 44 3.0 (1.0–10.3) 5.4 (5.7) 0.0–20.0 18.2 2.3
Time 2
CAMPHOR
Symptoms 42 5.0 (1.8–16.3) 8.3 (7.9) 0.0–25.0 16.7 2.4
Activities 44 6.0 (4.0–12.0) 9.2 (7.2) 0.0–30.0 2.3 2.3
QoL 42 4.5 (0.8–13.0) 7.2 (7.1) 0.0–25.0 23.8 2.4
NHP
Energy Scale 45 0.0 (0.0–33.3) 25.9 (37.5) 0.0–100.0 60.0 15.6
Pain Scale 42 0.0 (0.0–33.3) 18.5 (29.5) 0.0–100.0 57.1 2.4
Emotional Reactions 42 16.7 (0.0–33.3) 25.7 (28.8) 0.0–100.0 26.2 4.8
Sleep Scale 45 20.0 (0.0–60.0) 28.9 (34.8) 0.0–100.0 44.4 11.1
Social Isolation 43 0.0 (0.0–40.0) 15.3 (26.8) 0.0–100.0 69.8 2.3
Physical Mobility 44 25.0 (0.0–46.9) 26.4 (26.3) 0.0–100.0 29.5 2.3
NHP-D 39 3.0 (0.0–8.0) 5.3 (6.3) 0.0–23.0 25.6 2.6
Abbreviations: CAMPHOR Cambridge Pulmonary Hypertension Outcome Review, IRQ inter-quartile range, Max Maximum, Min minimum, QoL quality of life, NHP
Nottingham Health Profile
Table 4 Cronbach’s Alpha coefficients for Time 1 and Time 2
Instruments Reliability coefficient
Time 1
(n = 50)
Time 2
(n = 47)
CAMPHOR
Symptoms 0.95 0.95
Activities 0.93 0.95
QoL 0.94 0.94
Abbreviations: CAMPHOR Cambridge Pulmonary Hypertension Outcome
Review, NHP Nottingham Health Profile, QoL quality of Life
Table 5 Correlation coefficients between CAMPHOR scales and
NHP
Parameters Symptoms
(n = 50)
Activities
(n = 50)
QoL
(n = 50)
NHP
Energy Scale 0.82a 0.76a 0.75a
Pain Scale 0.66a 0.67a 0.56a
Emotional Reactions 0.78a 0.66a 0.78a
Sleep Scale 0.40a 0.47a 0.55a
Social Isolation 0.52a 0.40a 0.61a
Physical Mobility 0.83a 0.84a 0.77a
NHP-D 0.80a 0.72a 0.82a
Abbreviations: CAMPHOR Cambridge Pulmonary Hypertension Outcome
Review, NHP Nottingham Health Profile, QoL quality of life
aCorrelation is significant at the 0.01 level
Reis et al. Health and Quality of Life Outcomes  (2016) 14:110 Page 5 of 7
use of our version in other Portuguese-speaking countries
cannot be recommended, due to significant differences in
culture, literacy and language (both in terms of semantics
and vocabulary).
Most of the patients in the cognitive debriefing panels
reported that the instrument was easy to complete and
all patients reported that the questionnaire covered all
important aspects of their experience with the disease.
Three patients needed, nonetheless, additional informa-
tion to fully understand the instructions during the cog-
nitive debriefing interviews; these were older patients,
from rural settings and with low literacy skills, and after
additional clarifications, they finally were able to under-
stand the instructions. In our study, patients took a mean
of 17 min to complete the questionnaire, which is sub-
stantially longer than patients in the original instrument
(10 min) [30] and more in line with data from the German
translation (15 min) [34]. We hypothesise that this longer
completion time could be associated with lower literacy
and higher proportions of patients from rural contexts in
our population, however, literacy was not evaluated in our
sample hampering further clarification.
In this study, the proportion of patients reaching max-
imum scores in the CAMPHOR QoL scale was surpris-
ingly high, particularly when compared to previous
validation studies (16.3 % vs. 0.0–0.7 % in other studies
[13, 30–34]), which could be suggestive of a substantial
ceiling effect. These results, could potentially be explained
by disease severity, comorbidities, oxygen use, or even lit-
eracy. However, the proportion of patients reaching max-
imum scores is actually similar (or even higher) in the
NHP comparator scale, which could be indicative of a ten-
dency to the extremes in this population rather than a sub-
stantial ceiling effect. Given the similar results observed in
the NHP comparator scale we do not envision this possible
ceiling effect as a major limitation to the clinical use of this
European Portuguese translation of CAMPHOR.
We found significant relationships between the CAM-
PHOR scales and the relevant domains of the NHP and
the magnitude of the correlations followed a similar pat-
tern to those described in the original development study
[30]. The CAMPHOR also showed evidence of known
group validity in its ability to distinguish between groups
of patients known to differ between self-ratings of disease
severity and general health. The study showed that pa-
tients with precapillary PH experienced diminished QoL
and increased symptoms and functional limitations. Re-
sults are consistent with the findings that patients with
PH experience impairment in HRQoL [32, 33].
The major limitation of the present study is the small
sample size, but given the low prevalence of precapillary
PH related disease it can be considered an adequate sam-
ple for the purpose. Further studies to demonstrate CAM-
PHOR clinical validity, namely correlations with NYHA/
WHO functional class, 6MWD and biomarkers, in the
Portuguese population are being conducted.
Conclusions
In conclusion, this study gave sufficient evidence that our
adaptation of CAMPHOR is an effective and consistent
tool in European Portuguese-speaking population with
precapillary PH. Incorporating this questionnaire in future
clinical trials and especially in clinical practice will improve
our global clinical evaluation of the PH patient and will
improve knowledge of the health impact of PH. Routine
HRQoL evaluation at first presentation and regularly dur-
ing follow-up can help to educate/familiarize the patient
with these tools and help physicians make evidence-based
decisions.
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